Compare FNKO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7M | 202.1M |
| IPO Year | 2017 | 2016 |
| Metric | FNKO | EDIT |
|---|---|---|
| Price | $3.62 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $5.50 | $4.50 |
| AVG Volume (30 Days) | 792.0K | ★ 1.9M |
| Earning Date | 03-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $928,842,000.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $0.91 |
| 52 Week High | $14.28 | $4.54 |
| Indicator | FNKO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 39.21 |
| Support Level | $3.47 | $1.99 |
| Resistance Level | $3.77 | $2.28 |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 49.32 | 23.08 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.